Publications:

Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

Molecular Oncology

Feiersinger, Gertrud E GE; Trattnig, Kristina K; Leitner, Peter D PD; Guggenberger, Fabian F; Oberhuber, Alexander A; Peer, Sarah S; Hermann, Martin M; Skvortsova, Ira I; Vrbkova, Jana J; Bouchal, Jan J; Culig, Zoran Z; Santer, Frédéric R FR

Publication Date: 2018-04

Variant appearance in text: UNC5B: T683I

PubMed Link: 29465803

Variant Present in the following documents:

• MOL2-12-561-s006.xlsx, sheet 5

View BVdb publication page